Literature DB >> 18383533

Oculomotor function in multiple system atrophy: clinical and laboratory features in 30 patients.

Tim Anderson1, Linda Luxon2, Niall Quinn3, Susan Daniel4, C David Marsden1, Adolfo Bronstein2,5.   

Abstract

We reviewed the clinical and laboratory oculomotor features in 30 patients with probable multiple system atrophy (MSA), 22 with MSA-P and 8 with MSA-C. Six patients were also examined post mortem, MSA being confirmed in four and excluded in two (Parkinson's disease and progressive supranuclear palsy). Clinical examination showed the following abnormalities; excessive square wave jerks--21 of 30 patients; mild vertical supranuclear gaze palsy--8 of 30; gaze-evoked nystagmus--12 of 30 patients, three of whom had no extraocular evidence of cerebellar dysfunction; positioning downbeat nystagmus--10 of 25; mild or moderate saccadic hypometria--22 of 30; impaired ("broken up") smooth pursuit--28 of 30; reduced VOR suppression--16 of 24. Electro-oculography and caloric testing did not add significant extra information. In patients presenting with an akinetic-rigid syndrome it can be difficult to differentiate idiopathic Parkinson's disease from MSA-P and other causes of atypical parkinsonism. Our findings suggest that the presence of excessive square wave jerks, mild-moderate hypometria of saccades, impaired VOR suppression, spontaneous nystagmus or positioning downbeat nystagmus may be oculomotor "red flags" or clues to the presence of MSA. Further, the presence of clinically slow saccades, or moderate-to-severe gaze restriction, suggests a diagnosis other than MSA.

Entities:  

Mesh:

Year:  2008        PMID: 18383533     DOI: 10.1002/mds.21999

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  24 in total

1.  Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS.

Authors:  David J Szmulewicz; Catriona A McLean; Michael L Rodriguez; Andrew M Chancellor; Stuart Mossman; Duncan Lamont; Leslie Roberts; Elsdon Storey; G Michael Halmagyi
Journal:  Neurology       Date:  2014-03-28       Impact factor: 9.910

Review 2.  Diagnosis and differential diagnosis of MSA: boundary issues.

Authors:  Han-Joon Kim; Beom S Jeon; Kurt A Jellinger
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

Review 3.  Vertical supranuclear gaze palsy in Niemann-Pick type C disease.

Authors:  Ettore Salsano; Chizoba Umeh; Alessandra Rufa; Davide Pareyson; David S Zee
Journal:  Neurol Sci       Date:  2012-07-19       Impact factor: 3.307

4.  Pathologic correlates of supranuclear gaze palsy with parkinsonism.

Authors:  W R W Martin; J Hartlein; B A Racette; N Cairns; J S Perlmutter
Journal:  Parkinsonism Relat Disord       Date:  2017-02-24       Impact factor: 4.891

5.  Impaired oculomotor function in a community-based patient population with newly diagnosed idiopathic parkinsonism.

Authors:  Jan Linder; Britt-Inger Wenngren; Hans Stenlund; Lars Forsgren
Journal:  J Neurol       Date:  2011-12-16       Impact factor: 4.849

Review 6.  Eye Movement Disorders in Movement Disorders.

Authors:  Panagiotis Kassavetis; Diego Kaski; Tim Anderson; Mark Hallett
Journal:  Mov Disord Clin Pract       Date:  2022-02-16

Review 7.  Diagnosis of multiple system atrophy.

Authors:  Jose-Alberto Palma; Lucy Norcliffe-Kaufmann; Horacio Kaufmann
Journal:  Auton Neurosci       Date:  2017-10-23       Impact factor: 3.145

Review 8.  Eye movements in patients with neurodegenerative disorders.

Authors:  Tim J Anderson; Michael R MacAskill
Journal:  Nat Rev Neurol       Date:  2013-01-22       Impact factor: 42.937

Review 9.  Recent developments in multiple system atrophy.

Authors:  Gregor K Wenning; Nadia Stefanova
Journal:  J Neurol       Date:  2009-05-27       Impact factor: 4.849

10.  Comparison of smooth pursuit eye movement deficits in multiple system atrophy and Parkinson's disease.

Authors:  Elmar H Pinkhardt; Jan Kassubek; Sigurd Süssmuth; Albert C Ludolph; Wolfgang Becker; Reinhart Jürgens
Journal:  J Neurol       Date:  2009-04-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.